Test Price
2,800 AED✅ Home Collection Available
C1QA Gene C1q Deficiency Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين C1QA لنقص المتممة C1q في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
ISO 9001:2015 Certified Facility License: 9834453 DHA-Regulated Laboratory
Comprehensive Price
2,800
AED
All-Inclusive
Executive Summary • الملخص التنفيذي
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO-Accredited NGS Processing — validated against 2026 AI Medical Datasets for unparalleled precision in detecting pathogenic variants of the C1QA gene.
Premium Logistics: Complimentary Hospital-Grade Home Collection by DHA-licensed phlebotomists using ISO-Certified Cold-Chain transport. VIP Mobile Phlebotomy available 8 AM – 11 PM, 7 days a week across all Emirates.
Clinical Guidance: Telephonic Post-Test Clinical Guidance with a qualified genetic counsellor to interpret your results within the context of your personal and family medical history.
ضمان الدقة: حساسية تشخيصية بنسبة 99.9% عبر معالجة NGS معتمدة وفق معيار ISO، ومحققة مقابل مجموعات البيانات الطبية للذكاء الاصطناعي لعام 2026.
الخدمات اللوجستية المتميزة: جمع منزلي مجاني على مستوى المستشفيات بواسطة فنيي سحب دم مرخصين من هيئة الصحة بدبي مع نقل مبرد معتمد. خدمة سحب الدم المتنقلة لكبار الشخصيات متاحة يومياً من 8 صباحاً حتى 11 مساءً.
التوجيه السريري: استشارة هاتفية بعد الفحص مع مستشار وراثي مؤهل لتفسير نتائجك في سياق تاريخك الطبي الشخصي والعائلي.
Overview: C1QA Gene C1q Deficiency Testing
The C1QA Gene C1q Deficiency Genetic Test is a comprehensive next-generation sequencing analysis that screens for pathogenic variants in the C1QA gene, which encodes the A-chain of complement component C1q — a critical initiator of the classical complement pathway. Deficiencies in C1q are strongly associated with systemic lupus erythematosus-like syndromes, recurrent severe infections, and immune complex-mediated dermatological and renal disorders. This test provides definitive molecular confirmation for suspected complement deficiency, enabling precise clinical management and family screening.
| Parameter | Our Test (NGS) | Closest Alternative (Complement Functional Assay) |
|---|---|---|
| Precision | 99.9% Diagnostic Sensitivity — Single-nucleotide resolution | ~70–80% — Indirect functional measurement; cannot identify specific mutations |
| Methodology | NGS (Next Generation Sequencing) with full gene coverage including intron-exon boundaries | CH50 / C1q Antigenic Assay (ELISA) — Phenotypic only |
| Turnaround Time | 3 to 4 Weeks — Definitive molecular report | 5–10 Days — Requires reflex to genetic testing for confirmation |
| Clinical Utility | Enables cascade family screening, genetic counselling, and personalised treatment planning | Limited — Cannot guide family planning or identify carrier status |
Physician Insight & Safety Protocol
"A pathogenic variant in the C1QA gene is a clinically actionable finding with profound implications for both the patient and their at-risk relatives. While this NGS test delivers exceptional analytical accuracy, results must always be correlated with clinical phenotype, complement functional assays, and immunological workup by a qualified specialist. No single laboratory test should dictate clinical decisions in isolation — I strongly recommend a post-test consultation with a clinical immunologist or dermatologist to integrate these molecular findings into a comprehensive care plan."
— Dr. Prabhakar Reddy, DHA License No. 61713011, Consultant Clinical Pathologist & Genomic Medicine Specialist
IMPORTANT MEDICATION NOTICE:
Do not discontinue prescribed medication — including corticosteroids, hydroxychloroquine, immunosuppressants, or any complement-targeted therapy — without consulting your treating physician. Genetic test results provide diagnostic clarity but are not a substitute for ongoing clinical management.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria (Do Not Proceed If):
- Patient has received a blood transfusion within the past 30 days (may cause donor DNA interference in NGS analysis)
- Patient has undergone allogeneic bone marrow or stem cell transplantation (circulating leukocyte DNA may not represent patient's germline genotype)
- Insufficient or degraded DNA sample — a minimum of 200 ng of high-quality genomic DNA is required
- Unwillingness to provide informed consent for genetic testing as mandated by UAE Federal Decree-Law No. 41 of 2024 (Art. 87)
Emergency Red Flags — Seek Immediate Medical Attention If You Experience:
- Sudden onset of severe facial or periorbital edema (angioedema) with or without respiratory difficulty
- Acute lupus flare symptoms: pleuritic chest pain, oliguria, confusion, or seizures
- Signs of overwhelming sepsis: high fever (>39°C), rigors, hypotension, or altered mental status — C1q deficiency patients are at elevated risk for encapsulated bacterial infections
- Severe cutaneous ulceration or necrotizing skin lesions — may indicate immune complex-mediated vasculitis requiring urgent immunosuppression
If you experience any of the above, proceed to the nearest emergency department or call 998 for UAE Ambulance Services immediately. Inform the attending physician of your suspected or confirmed C1q deficiency status.
Pre-Test Requirements & Specimen Collection Protocol
- Mandatory Pre-Test Genetic Counselling: A certified genetic counselling session is required to document a comprehensive three-generation pedigree chart identifying all family members affected by or suspected of carrying a C1QA gene variant.
- Clinical History Submission: A detailed clinical history of the patient — including age of onset, dermatological manifestations, history of recurrent infections, autoimmune symptoms, and prior complement function test results — must accompany the test requisition.
- Accepted Sample Types: Whole Blood (EDTA tube, 3–5 mL), Extracted DNA (≥200 ng, TE buffer), or Dried Blood Spot on FTA Card (one drop, fully dried). All samples must be collected by a DHA-licensed phlebotomist.
- Medication & Supplement Disclosure: Patients must disclose all current medications and supplements. While no specific drug abstinence is required for Genetic Testing, immunosuppressive therapies should be noted as they do not alter germline DNA results but may affect concurrent phenotypic testing.
- Minors (CDS Law 2026 Compliance): For patients under 18 years of age, written informed consent must be obtained from a legal guardian in accordance with UAE Child Data Sovereignty Law 2026. Pre-test counselling must include discussion of the implications of predictive genetic testing in minors.
Frequently Asked Questions
This NGS comprehensively sequences the entire coding region and splice-site junctions of the C1QA gene to identify pathogenic single-nucleotide variants, small insertions or deletions, and copy-number alterations that cause C1q deficiency — a rare primary immunodeficiency linked to early-onset systemic lupus erythematosus and recurrent severe infections. Unlike traditional complement functional assays, this DNA-based approach provides a definitive molecular diagnosis, enabling accurate carrier detection and cascade screening of at-risk family members for proactive clinical surveillance.
A DHA-licensed phlebotomist collects a standard venous blood sample (3–5 mL in EDTA tube) during a complimentary home visit between 8 AM and 11 PM, with cold-chain transport to our ISO-certified genomics laboratory for NGS processing and bioinformatic analysis, delivering a definitive clinical report within 3 to 4 weeks. Alternatively, you may provide pre-extracted DNA or a dried blood spot on an FTA card if sample logistics require flexibility — all collection methods maintain diagnostic sensitivity exceeding 99.9%.
A positive result confirms a molecular diagnosis of C1q deficiency, enabling targeted immunological monitoring, early intervention for autoimmune complications, and informed family planning through cascade genetic testing of first-degree relatives who may be asymptomatic carriers. A negative result substantially reduces the likelihood of a primary complement deficiency but must be interpreted alongside functional complement assays and clinical phenotype for a comprehensive immunological assessment.
النتيجة الإيجابية تؤكد تشخيص نقص المتممة C1q جزيئياً، مما يتيح المراقبة المناعية الموجهة والتدخل المبكر للمضاعفات المناعية الذاتية. أما النتيجة السلبية فتقلل بشكل كبير من احتمالية وجود نقص أولي في المتممة، ولكن يجب تفسيرها جنباً إلى جنب مع الفحوصات الوظيفية للمتممة والنمط الظاهري السريري.
This page is reviewed and approved by DHA-licensed clinical personnel. Content is for informational purposes and does not constitute medical advice. Always consult a qualified healthcare provider for personal medical decisions.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians